Literature DB >> 389600

Glipizide: a review of its pharmacological properties and therapeutic use.

R N Brogden, R C Heel, G E Pakes, T M Speight, G S Avery.   

Abstract

Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites which are excreted in the urine. Therapeutic trials have shown the efficacy of glipizide in maturity onset diabetes mellitus to be comparable with that of glibenclamide and chlorpropamide in newly diagnosed patients unresponsive to diet as well as in patients previously treated with oral hypoglycaemic drugs. Glipizide is well tolerated, but careful adjustment of dosage and attention to diet may be needed to avoid hypoglycaemic symptoms a few hours after a single daily dose.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389600     DOI: 10.2165/00003495-197918050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  45 in total

1.  Glipizide--a new oral antidiabetic.

Authors:  A M El Saadani; A Gaber
Journal:  J Egypt Med Assoc       Date:  1975

2.  [Clinical experimentation with a new hypoglycemic agent (glipizide)].

Authors:  C Forattini
Journal:  Minerva Med       Date:  1972-10-06       Impact factor: 4.806

3.  [Evaluation of a new sulfonylurea, glipizide, in the treatment of diabetes mellitus].

Authors:  M Ninni; L Castelletta
Journal:  Minerva Med       Date:  1973-10-10       Impact factor: 4.806

4.  Clinical study with glipizide, a new oral antidiabetic drug.

Authors:  G Persson
Journal:  Diabetologia       Date:  1973-09       Impact factor: 10.122

5.  Effect of glipizide on the release of insulin in the perfused rat pancreas in vitro.

Authors:  Y Tasaka; M Sekine; C Sugimoto; H Ogawara; K Shizume
Journal:  Endocrinol Jpn       Date:  1974-06

6.  Clinical and metabolic observations with a new synthetic oral antidiabetic agent, glipizide.

Authors:  F D'Onofrio; R Pempinello; L Romis
Journal:  Arzneimittelforschung       Date:  1972-11

7.  Diazoxide, glipizide, and hypoglycaemia.

Authors:  R H Greenwood; R F Mahler; C N Hales
Journal:  Lancet       Date:  1977-02-05       Impact factor: 79.321

8.  Diazoxide, glipizide, hypertension and hypoglycaemia.

Authors:  M J Farr
Journal:  Lancet       Date:  1976-11-20       Impact factor: 79.321

9.  Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.

Authors:  D Artini; R Abbiati; G Orsini; M A Parenti; K Bloch; S Daturi; V Mandelli
Journal:  Diabetologia       Date:  1973-09       Impact factor: 10.122

10.  [Changes in insulin (IRI) and NEFA levels in diabetic subjects after acute intravenous glipizide and tolbutamide administration].

Authors:  S Fedeli; A Maglia
Journal:  Arch Sci Med (Torino)       Date:  1977 Jan-Mar
View more
  10 in total

Review 1.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

3.  Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers.

Authors:  Sanju Dhawan; Bhupinder Singh; Santosh Kumar Garg; Debasish Hota; Radharaman Jiban Dash; Anil Kumar Singla; Vivek Ranjan Sinha
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

Authors:  J E Jackson; R Bressler
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.

Authors:  L Balant
Journal:  Clin Pharmacokinet       Date:  1981 May-Jun       Impact factor: 6.447

Review 6.  The management of diabetes mellitus in older individuals.

Authors:  J E Morley; H M Perry
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 7.  Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

8.  Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.

Authors:  E Wåhlin-Boll; L O Almér; A Melander
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

9.  The enhancing effect of ion-pairing on the skin permeation of glipizide.

Authors:  Zhe Tan; Jingying Zhang; Jian Wu; Liang Fang; Zhonggui He
Journal:  AAPS PharmSciTech       Date:  2009-07-28       Impact factor: 3.246

Review 10.  Pharmacogenetics of warfarin elimination and its clinical implications.

Authors:  H Takahashi; H Echizen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.